Hamlet Pharma Starts Two Parallel Clinical Study Programs
Hamlet Pharma is pleased to announce that the clinical development of Alpha1H therapy in bladder cancer will be accelerated. Two studies will be conducted in parallel; a dose-escalation study, which will examine the efficacy of higher Alpha1H concentrations and a combination study, combining Alpha1H with a currently used chemotherapeutic agent.Today Hamlet Pharma has received the permission from the Czech authorities to resume its clinical trial activities, together with the team in Prague. The dose-escalation and combination therapy studies will both be conducted, simultaneously. There